These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8452652)

  • 1. Human antibodies to HIV-1 by recombinant DNA methods.
    Burton DR; Barbas CF
    Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
    Zhang MY; Shu Y; Sidorov I; Dimitrov DS
    Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications.
    Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E
    Year Immunol; 1993; 7():63-8. PubMed ID: 7690509
    [No Abstract]   [Full Text] [Related]  

  • 5. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
    Laal S; Zolla-Pazner S
    Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
    Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
    Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs.
    Koefoed K; Farnaes L; Wang M; Svejgaard A; Burton DR; Ditzel HJ
    J Immunol Methods; 2005 Feb; 297(1-2):187-201. PubMed ID: 15777942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary crystallographic studies of an anti-HIV-1 protease antibody that inhibits enzyme activity.
    Lescar J; Stouracova R; Riottot MM; Chitarra V; Brynda J; Fabry M; Horejsi M; Sedlacek J; Bentley GA
    Protein Sci; 1996 May; 5(5):966-8. PubMed ID: 8732768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120.
    Wang HW; Cole D; Jiang WZ; Jin HT; Fu N; Chen ZL; Jin NY
    Clin Exp Immunol; 2005 Jul; 141(1):72-80. PubMed ID: 15958072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
    Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.
    Major JG; Liou RS; Sun LK; Yu LM; Starnes SM; Fung MS; Chang TW; Chang NT
    Hum Antibodies Hybridomas; 1994; 5(1-2):9-17. PubMed ID: 7858187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of synthetic peptides for the production of site (amino acid) specific polyclonal and monoclonal antibodies.
    Claassen E; Zegers ND; Laman JD; Boersma WJ
    Year Immunol; 1993; 7():150-61. PubMed ID: 7690507
    [No Abstract]   [Full Text] [Related]  

  • 18. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.